We have located links that may give you full text access.
Diagnostic value of additional 68 Ga-PSMA-PET before 223 Ra-dichloride therapy in patients with metastatic prostate carcinoma.
Nuklearmedizin. Nuclear Medicine 2017 Februrary 15
PURPOSE: Medical imaging plays an important role in selecting patients with metastatic castration-resistant prostate cancer for 223 Ra-dichloride therapy of bone metastases. The purpose of this study was to investigate whether 68 Ga-PSMA-PET has incremental value over conventional imaging for selecting patients suitable for 223 Ra-dichloride therapy.
METHODS: In 27 consecutive patients referred for 223 Ra-dichloride therapy additional 68 Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy.
RESULTS: In 4 patients (15 %) 68 Ga-PSMA-PET revealed previously unknown visceral metastases (3 liver, 1 adrenal gland), which changed the therapeutic decision in 2 cases. PET revealed more extended tumour involvement in the bone compared to bone scintigraphy in 9 patients (33 %). In 3 of these, the mismatch was extensive enough to question suitability for 223 Ra-dichloride therapy.
CONCLUSIONS: Additional 68 Ga-PSMA-PET as a gatekeeper between conventional staging and 223 Ra-dichloride therapy can provide valuable additional information with regard to visceral metastases and tumour manifestations without adequate bone mineral turnover. It may lead to a change in therapeutic management in a significant number of patients and should therefore be considered in future clinical trials.
METHODS: In 27 consecutive patients referred for 223 Ra-dichloride therapy additional 68 Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy.
RESULTS: In 4 patients (15 %) 68 Ga-PSMA-PET revealed previously unknown visceral metastases (3 liver, 1 adrenal gland), which changed the therapeutic decision in 2 cases. PET revealed more extended tumour involvement in the bone compared to bone scintigraphy in 9 patients (33 %). In 3 of these, the mismatch was extensive enough to question suitability for 223 Ra-dichloride therapy.
CONCLUSIONS: Additional 68 Ga-PSMA-PET as a gatekeeper between conventional staging and 223 Ra-dichloride therapy can provide valuable additional information with regard to visceral metastases and tumour manifestations without adequate bone mineral turnover. It may lead to a change in therapeutic management in a significant number of patients and should therefore be considered in future clinical trials.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app